source
- Bayer's asundexian receives FDA approval for stroke preventionBayer announced that the U.S. Food and Drug Administration has approved its oral anticoagulant asundexian for stroke prevention. The drug is indicated to lower the risk of subsequent stroke in pati…
- London startup Oyster Therapeutics raises $60M to develop oral tau degraders for Alzheimer’sOyster Therapeutics, a London‑based biotech, announced it has closed a $60 million Series A‑2 financing round. The round was led by 4BIO Capital, a life‑science venture capital firm, with addition…